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We have characterized at the molecular level, three families with core myopathies carrying apparent
recessive mutations in their RYR1 gene and studied the pharmacological properties of myotubes carrying
endogenous mutations as well as the properties of mutant channels expressed in HEK293 cells. The proband
of family 1 carried p.Ala1577Thr1 p.Gly2060Cys in trans, having inherited a mutation from each parent.
Immunoblot analysis of proteins from the patient’s skeletal muscle revealed low levels of ryanodine receptor
(RyR1) but neither substitution alone or in combination affected the functional properties of RyR1 channels in
a discernable way. Two affected siblings in family 2 carried p.Arg109Trp1 p.Met485Val substitutions in cis,
inherited from the unaffected father. Interestingly, both affected siblings only transcribed the mutated
paternal allele in skeletal muscle, whereas the maternal allele was silent. Single-channel measurements
showed that recombinant, mutant RyR1 channels carrying both substitutions lost the ability to conduct
Ca21. In this case as well, low levels of RyR1 were present in skeletal muscle extracts. The proband of
family 3 carried p.Ser71Tyr1 p.Asn2283His substitutions in trans. Recombinant channels with Asn2283His
substitution showed an increased activity, whereas recombinant channels with p.Ser71Tyr1 p.Asn2283His
substitution lost activity upon isolation. Taken together, our data suggest major differences in the ways
RYR1 mutations may affect patients with core myopathies, by compromising RyR1 protein expression,
stability and/or activity.
INTRODUCTION
The skeletal muscle ryanodine receptor (RYR1) gene encodes
the sarcoplasmic reticulum junctional face membrane calcium
release channel ryanodine receptor (RyR1), which plays a
crucial role in excitation–contraction (E–C) coupling (1–6).
The RyR1 ion channels are large protein complexes composed
of four RyR 560 kDa peptides and various associated proteins
with a total molecular weight of .2500 kDa. They play a
crucial role in skeletal muscle E–C coupling by releasing
calcium ions required for muscle contraction from the sarco-
plasmic reticulum. Disease phenotypes associated with more
than 80 dominant RYR1 mutations identified to date include
central core disease (CCD) (OMIM no. 117000) and the
malignant hyperthermia susceptibility (MHS) trait (MH;
OMIM no. 145600) (reviewed in 7–10). More recently, few
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recessive mutations have been reported in association with
patients affected by multi-minicore disease (MmD) (OMIM
no. 602771) (11–14) and forms of CCD with unusual or
more severe presentations (15). MHS-related RYR1 mutations
are predominantly located in the hydrophilic N-terminal and
central portions of the RyR1 protein, whereas CCD-related
RYR1 substitutions mainly occur in the hydrophobic
pore-forming region of the channel (16–21). To date, only
few recessive RYR1 mutations have been identified and they
appear to be distributed throughout the entire gene
(11,12,14) (Zhou et al., personal communication).
Investigation on the functional properties of RYR1
mutations is crucial for the understanding of the molecular
mechanisms associated with RYR1-related clinical pheno-
types. Although it is widely accepted that MH-causing RYR1
mutations increase the sensitivity of the RyR1 to activation
by pharmacological reagents such as caffeine or
4-chloro-m-cresol (22–26) and CCD mutations attenuate
channel activity and Ca2þ conductance (20,21,26–29), the
molecular mechanisms associated with recessively inherited
RYR1-related phenotypes are currently only partially
understood (30).
In the following report, we identified RYR1 mutations in
three families with clinical features of a congenital myopathy
with multiple cores on muscle biopsy. Functional properties of
these RYR1 mutants were distinct from those previously
reported in CCD and depended on the substituted residues
and their location: (i) the presence of the p.Ala1577Thrþ
p.Gly2060Cys substitutions in trans (in family 1) reduced
RyR1 expression level, without noticeably affecting the func-
tional properties of the recombinant RyR1 ion channel; (ii) the
compound p.Arg109Trpþ p.Met485Val substitutions in cis in
family 2 also reduced the endogenous RyR1 expression level
in muscle, but in addition affected the ability of recombinant
channels expressing both substitutions to conduct Ca2þ; (iii)
the p.Ser71Tyr and p.Asn2283His substitutions in trans in
family 3 affected both channel stability and activity. These
results suggest that some RYR1 mutations may not only
affect Ca2þ homeostasis directly, but also impair RyR1 func-
tion because they significantly affect the stability of the RyR1
complex. Finally, this report shows that in some patients har-
bouring RYR1 mutations the disease phenotype is associated
with silencing of the ‘normal’ allele.
RESULTS
Patient phenotype, mutation screening, histological
examination and family history
In this study, we examined four patients from three different
families displaying a similar clinical phenotype: all patients
presented clinical manifestations during the neonatal period
showing muscle weakness, hypotonia and feeding difficulties,
followed by delayed motor milestones. One of the two siblings
in family 2 required prolonged ventilation in the neonatal
period; the affected child in family 3 had bilateral hip dyspla-
sia for which he was operated at the age of 3 months; the
propositus in family 1 had bilateral talipes for which surgery
was performed at the age of 10 months. Marked axial weak-
ness and feeding difficulties with subsequent poor weight
gain characterized all affected children, requiring gastostomy
intervention in the two siblings of family 2 who also had
ophthalmoplegia. All affected children acquired the ability
to walk, although late, between 18 and 24 months, and they
remain ambulant but only for relatively short distance. They
all have difficulties in rising from the floor and climbing
stairs; respiratory muscle weakness leading to frequent chest
infection was a particularly prominent feature in families 1
and 2 and indicates a more severe phenotype of these families
compared with family 3.
Figure 1 shows the family tree and genetic characterization
of the patients and their family members studied. The three
families carried compound heterozygous substitutions in
their RYR1. Screening of the entire RYR1 cDNA was per-
formed in order to exclude the presence of other amino acid
substitutions.
In family 1, the p.Ala1577Thr substitution was transmitted
from the mother and was not found in 100 control chromo-
somes, whereas the paternally transmitted p.Gly2060Cys sub-
stitution was previously reported as a polymorphism (7,31).
We determined the frequency of the polymorphic
p.Gly2060Cys substitution in 50 individuals of the general
population and 28 patients affected by core myopathies.
Seven controls and four patients carried this variation, indicat-
ing a similar distribution in the two populations, further
suggesting this to be a polymorphism.
The two siblings in family 2 showed transcription of only one
allele in muscle, whereas they clearly carried two alleles at the
genomic level. These patients transcribed in muscle the allele con-
taining the two substitutions p.Arg109Trp and p.Met485Val,
inherited from the asymptomatic father. However, p.Met485 is
not a conserved residue and shows as leucine in all other
species, suggesting it probably as a polymorphism.
In family 3, the patient harbours two substitutions,
p.Ser71Tyr and p.Asn2283His transmitted each from one
asymptomatic parent. The monozygotic twins are apparently
asymptomatic but could not be studied genetically.
The presence of the mutations was confirmed by RT–PCR
analysis using myotubes derived from satellite cells in family
1 and using myotubes derived from skin fibroblasts transduced
with MyoD-encoding adenovirus in families 2 and 3 (dis-
cussed subsequently). Figure 1C shows the results obtained
after PCR amplification and sequencing. In the proband of
family 3, the cDNA from MyoD-transformed myotubes has
a genotype identical to that found in the patient’s muscle
tissue. Interestingly, in family 2, both the paternal and
maternal alleles were transcribed in the fibroblasts transduced
with MyoD. This clearly differed from the pattern of transcrip-
tion in the skeletal muscle biopsies, in which only the paternal
allele was transcribed (described earlier).
The histopathological features of the biopsies from the three
affected families are compatible with those now known to be
associated with RYR1 mutations. The muscle biopsy from
patient 1 showed mild variation in fibre size, an increase in
internal nuclei, some of which were central, and a little endo-
mysial connective tissue (Fig. 2A). Oxidative enzyme staining
revealed multiple focal areas devoid of stain, as well as some
single cores of moderate size, and some peripheral aggregation
of stain (Fig. 2D and G). Fibre typing was indistinct with
NADH-TR staining and most fibres expressed slow myosin.
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The biopsy from one affected child in family 2 showed a
wide variation in fibre size with atrophy and hypertrophy.
Several fibres had internal nuclei, many of which were
central (Fig. 2B). Some fibres also showed red stained
rod-like structures with the Gomori trichrome stain. Oxidative
enzyme stains showed large areas devoid of stain, and obli-
quely sectioned fibres suggested that these core areas were
focal but often spanned the width of the fibre (Fig. 2E and
H). Fibres with slow myosin were predominant.
The muscle biopsy from the affected child in family 3 showed
moderate variation in fibre size and no increase in internal nuclei
(Fig. 2C). Oxidative enzyme stains showed prominent core
areas in several fibres, which were often peripheral, as well as
unevenness of oxidative enzyme stain and uniform fibre
typing (Fig. 2F). No longitudinally sectioned fibres were
present from this biopsy to assess the length of the cores.
Immunoblot analysis of muscle samples
Western blot analysis on total protein extracts revealed low
levels of RyR1 in the total protein extract from the
muscle from patients of families 1 and 2 harbouring the
p.Ala1577Thrþ p.Gly2060Cys (Fig. 3, lane 1) and p.Arg
109Trpþ p.Met485Val (Fig. 3, lane 2) substitutions compared
with the control. Muscle samples from the p.Ser71Tyrþ
p.Asn2283His patient and control showed similar levels of
RyR1 (Fig. 3, lanes 3 and 4); the intensity of the immuno-
reactive band corresponding to desmin was similar in all
samples tested. The results suggest that the RyR1 mutations
in families 1 and 2 affect RyR1 protein expression and/or
stability.
MyoD-transduced fibroblasts express proteins
characteristic of differentiated skeletal muscle
We also considered the possibility that the amino acid substi-
tutions may compromise RyR1 function by performing cellu-
lar Ca2þ release measurements in myotubes. Because
myotubes derived from satellite cells of muscle biopsies are
not always available, and in our case were not available
from families 2 and 3, in initial experiments we tested
whether myotubes obtained by adenovirus-mediated MyoD
transduction of control skin fibroblasts could be used to
characterize the RyR1 mutants. Figure 4 shows indirect immu-
nofluorescence analyses of untransduced fibroblasts (left
panels) or skin fibroblasts from a control, transduced with
MyoD and differentiated for 5–7 days (right panels). We
found that the differentiated cells express markers of skeletal
muscle cells such as desmin and myosin; they also express
both the dihydropyridine receptor (DHPR) and the RyR1.
No immunoreactivity was present for these skeletal muscle
proteins in skin fibroblasts. Figure 5A shows that myotubes
derived from MyoD-transduced fibroblasts also express a
functional RyR1 ion channel, as stored Ca2þ could be released
via the DHPR, by adding 150 mM KCl (Fig. 5A) and pharma-
cologically by 4-chloro-m-cresol (which activates RyR1
independent of DHPR) (Fig. 5B). Figure 5C compares the sen-
sitivities to pharmacological activation of control myotubes
derived from differentiating myoblasts by serum deprivation
with those derived from control MyoD-transduced fibroblasts.
The peak of the Ca2þ transients elicited by agonist was deter-
mined and used to construct dose-dependence curves. Both
kinds of myotubes respond to KCl, 4-chloro-m-cresol and caf-
feine: the maximal increase in fluorescence and EC50 for
Figure 1. Pedigrees and genotyping data of the three families with mini-core myopathy investigated in the present study. (A) Pedigrees of the three families
carrying compound heterozygous mutations in their RYR1 gene. Black symbols: symptomatic core myopathy patients; open symbols: asymptomatic individuals;
half-black symbols: carriers; triangle symbol with line through: affected, termination of pregnancy; question marks: untested individuals. Plus indicates the pre-
sence of the mutated allele and minus indicates the presence of the normal allele. (B) Chromatograms obtained from sequencing muscle tissue RyR1 cDNA.
Arrows indicate the residues giving rise to nucleotides variations. At variance from the heterozygous variations identified in F1 and F3, the nucleotide variations
found in F2 show homozygous changes. (C) Chromatograms obtained from sequencing the RyR1 cDNA from myotubes obtained after myoD transduction of
skin fibroblasts. In F2, the nucleotide variations present as heterozygous changes were present both at the genomic level (data not shown) and at the transcrip-
tional level in myotubes derived from myoD-transduced fibroblasts, but as homozygous changes in muscle tissue. In F3, the genotypes of the cDNAs derived
from muscle and from myotubes derived from myoD-transduced fibroblasts are the same. (D) Chromatograms for the sequencing of WT muscle cDNA.
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KCl and caffeine was not significantly different (Fmax and
EC50 for KCl were 0.22+ 0.04 and 35.4+ 6.5 versus
0.25+ 0.03 and 30.7+ 3.0, and for caffeine, they were
0.29+ 0.028 and 6.3+ 0.54 versus 0.36+ 0.03 and
8.07+ 0.72 in control and MyoD myotubes, respectively).
Control and MyoD myotubes showed also similar peak Ca2þ
transient in the presence of 600 mM 4-chloro-m-cresol
(0.28+ 0.04 versus 0.29+ 0.03, respectively). However, at
higher agonist concentrations, the curve did not saturate in
MyoD myotubes, indicating that non-specific Ca2þ release
due to activation of other intracellular receptors/channels
might be occurring. These results confirm the validity of the
MyoD myotube model assessing the effects of RyR1
mutations on stored Ca2þ release, when satellite-cell-derived
myotubes from patients are not readily available.
Effect of RyR1 amino acid substitutions on resting
cytosolic Ca21 concentrations and stored Ca21 release
We used the fluorescent Ca2þ indicator Fura-2 to determine
whether the RYR1 mutations identified in the core myopathy
patients affected resting cytosolic Ca2þ concentrations
([Ca2þ]i) of myoD-tranduced myotubes obtained from (i)
compound heterozygous affected individuals, (ii) heterozy-
gous parents when available and (iii) control individuals
(Fig. 6). The resting fluorescence ratio observed in cells
from affected patients and healthy parents was not signifi-
cantly different from that observed in control cells, for all
amino acid substitutions, except for cells carrying the
p.Ser71Tyrþ p.Asn2283His RYR1 substitution
(P , 0.00001) (Fig. 6). Of interest, the resting [Ca2þ]i of myo-
tubes derived from MyoD-transduced fibroblasts was slightly
lower (10–20 nM) than that observed in myotubes derived
from primary muscle cultures.
Next we determined whether a decrease in SR Ca2þ release
was responsible for the weak muscle phenotype of the patients
harbouring recessive RYR1 mutations. Table 1 compares the
peak Ca2þ release (Rmax) obtained by treating myotubes
with KCl and caffeine. None of the substitutions caused a sig-
nificant decrease in the peak Ca2þ release when compared
with that observed from control cells or cells obtained from
unaffected family members. Of interest, cells carrying the
p.Ser71Tyrþ p.Asn2283His RYR1 substitution were more
sensitive to RyR1 activation and behaved like cells from
MHS individuals. Although peak Ca2þ release (Rmax) was
not significantly affected (Table 1), the EC50 was reduced by
~50% (from 20.1+ 0.03 to 10.7+ 0.04 for KCl and
6.1+ 1.2 to 1.9+ 0.1 for caffeine in MyoD myotubes from
control and p.Ser71Tyrþ p.Asn2283His, respectively).
Functional properties of mutant RYR1s expressed
in HEK293 cells
In order to gain a more comprehensive view of the effects of
the mutations on RyR1 channel function, we expressed rabbit
RyR1s carrying the recessive mutations in a heterologous
(HEK293) cell system that lacks endogenous RyRs. Note
that in the cells expressing the recombinant rabbit RyR1
cDNA, the rabbit nomenclature for residues is used. The
expression levels and functional properties of the recombinant
RyR1 mutants were determined by cellular fluorescence
microscopy, immunoblot analysis and [3H]ryanodine
binding. Single channels were recorded to determine the ion
permeation properties of the mutants.
The fluorescence change of Fluo-4 was measured to detect
Ca2þ release in response to 10 mM caffeine or 400 mM
4-chloro-m-cresol in HEK293 cells that expressed wild-type
(WT) and mutant RyR1s. Similar time courses and peak
amplitudes of Ca2þ release were observed for cells expressing
WT and Ala1578Thr, Ser2060Cys, Leu486Val, Ser71Tyr and
Asn2283His RYR1 mutant channels, whereas vector-
transfected cells and cells transfected with cDNAs carrying
Arg110Trp or Arg110Trpþ Leu486Val substitutions showed
Figure 2. Histolopathological features of muscle biopsies from patients with
core myopathy. Haematoxylin and eosin (A–C), NADH-TR (D and G) and
cytochrome oxidase (E, F and H). Note the increase in internal nuclei in
families 1 and 2 (A and B), and that fibre typing is indistinct all three
cases. In family 1, multiple cores are clearly seen (D and G); in family 2,
the prominent cores often span the width of the fibre (E and H) and
in family 3, the large cores are often peripheral and there is also uneven
staining (F).
Figure 3. Western blot of total protein extracts from skeletal muscle biopsies
of patients with RYR1 mutations. Lane 1: p.Ala1577Thrþ p.Gly2060Cys,
lane 2: p.Arg109Trpþ p.Met485Val, lane 3: p.Ser71Tyrþ p.Asn2283His,
lane 4: control. Thirty micrograms of proteins were loaded on a 3–8%
NuPAGE pre-cast gel and transferred electrophoretically to nitrocellulose
membrane; the blot was probed with anti-RyR1 and anti-desmin antibodies
as described in Materials and Methods. Desmin immunoreactivity was used
as muscle-specific internal control.
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no caffeine and 4-chloro-m-cresol response (data not shown).
Immunoblot analysis showed that the absence of caffeine
and 4-chloro-m-cresol responses was not due to lack of
protein expression as both the single and double RyR1
mutants were expressed in HEK293 cells at a level compar-
able to WT (data not shown).
The expression of functional RyR1 mutants was also
assessed by a [3H]ryanodine binding assay. Ryanodine binds
with high specificity to the RyRs and is widely used as a
probe of channel activity because of its preferential binding
to the open channel state (32). Membrane fractions isolated
from HEK293 cells expressing the Ala1578Thr, Ser2060Cys,
Leu486Val and Asn2283His RYR1 mutants bound [3H]ryano-
dine (Fig. 7A) and showed Ca2þ dependence of [3H]ryanodine
binding (Fig. 7B) close to those of WT-RyR1. Figure 7C
shows that caffeine increased [3H]ryanodine binding to micro-
somes harbouring WT RyR1 and RyR1s carrying the
Ala1578Thr, Ser2060Cys, Leu486Val and Asn2283His sub-
stitutions. Interestingly, Asn2283His recombinant channels
bound an increased amount of [3H]ryanodine (normalized to
Bmax value) in the absence of caffeine, however, without
showing an increased caffeine sensitivity. Two RyR1
mutants (Arg110Trp and Arg110Trpþ Leu486Val) showed
loss of high-affinity [3H]ryanodine binding (Fig. 7A), in
agreement with our observation that these two mutants
failed to show a caffeine or 4-chloro-m-cresol response in
HEK293 cells. RyR1-Ser71Tyr exhibited a caffeine and
4-chloro-m-cresol response in HEK293 cells but failed to
bind substantial amounts of [3H]ryanodine, which indicated
a loss of function during membrane isolation.
We also expressed in HEK293 cells RyR1-Ala1578Thr and
RyR1-Ser2060Cys or RyR1-Ser71Tyr and RyR1-Asn2283His
mutants in 1:1 ratio to match their simultaneous expression in
families 1 and 3. Co-expression of RyR1-Ala1578Thr and
RyR1-Ser2060Cys yielded a Bmax value (Fig. 7A) and Ca
2þ-
dependence (Fig. 7B) of [3H]ryanodine binding comparable
to those for membranes isolated from cells carrying the two
mutants alone. Co-expression of RyR1-Ser71Tyr and RyR1-
Asn2283His also showed the presence of functional RyR1
channels, albeit at a reduced level, as these cells exhibited a
Bmax value of [
3H]ryanodine binding intermediate to cells
expressing the two mutants alone.
Figure 8 compares single-channel activities and ion per-
meation properties of WT ion channels with two mutant
channels. Shown are RyR1-Asn2283His which exhibited an
apparent increased activity in [3H]ryanodine binding experi-
ments and RyR1-Arg110Trpþ Leu486Val which failed to
show a caffeine and 4-chloro-m-cresol response in HEK293
cells. Single-channel measurements were performed using the
planar lipid bilayer method. Proteoliposomes containing the
purified channels were fused with planar lipid bilayers, and
single channels were initially recorded in 250 mM KCl on
both sides of the bilayer with Kþ as the current carrier.
The cis (cytosolic) and trans (SR lumenal) bilayer chambers
contained micromolar-activating Ca2þ (2 mM). To ascertain
retention of pharmacological regulation, cytosolic Ca2þ
concentrations were reduced to 0.1 mM. To determine Ca2þ
currents (at 0 mV) as well as Ca2þ selectivity, WT and mutant
channels were recorded in 250 mM symmetrical KCl with
10 mM Ca2þ in the trans (SR lumenal) bilayer chamber. We
found that RyR1-Asn2283His showed an increased single-
channel open probability (Po) compared with WT at both 2
and 0.1 mM cis Ca2þ as well as with 10 mM trans Ca2þ as con-
ducting ion (Fig. 8A and B, Table 2). Kinetic analysis showed
that the mutation increased Po at 2 mM cytosolic Ca
2þ by
raising the mean open time without significantly changing the
number of single-channel events or mean close time (legend
of Fig. 8). Single-channel activities of RyR1-Arg110Trpþ
Leu486Val were high, but did not respond to a change in
cytosolic Ca2þ concentration (Fig. 8A, Table 2). Moreover, no
single-channel currents were measured at 0 mV with 10 mM
Ca2þ in the trans chamber.
Kþ currents of WT, Arg110Trpþ Leu486Val and
Asn2283His RyR1 channels, measured in symmetrical
250 mM KCl, showed a linear voltage-dependence (Fig. 8C).
Single-channel conductances were not different for WT and
RyR-Asn2283His but were highly variable for RyR
Asn2283His, yielding an averaged reduced Kþ conductance
of 442+ 77 pS (Table 2). In the presence of 10 mM Ca2þ
trans at 0 mV, Asn2283His exhibited a unitary Ca2þ current
essentially identical to that of WT RyR1 (Fig. 8C, Table 2).
Figure 4. Photomicrograph of cultured skin fibroblasts before and after MyoD
transduction and differentiation into myobasts. Left: fibroblasts established
from skin biopsies and cultured as described in Materials and Methods.
Right: myotubes derived from MyoD transduction and cultured in diff-
erentiation medium for 5–8 days. Panels show photomicrographs of cells
after indirect immunofluorescence staining for MyoD, desmin, myosin, a1.1
subunit of the DHPR and skeletal muscle RyR1. (20  0.5 HC PL
FLUOTAR objective).
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Single-channel currents were reduced at elevated positive and
negative potentials, and the reversal potentials (Erev) for WT
RyR1 and RyR-Asn2283His were shifted by þ9.5 and
þ12.6 mV, respectively. Applying constant field theory, a per-
meability ratio of Ca2þ over Kþ (PCa/PK) of 7.0 and 10.6 was
calculated for WT and Asn2283His RyR1 channels, respect-
ively (Table 2). In contrast, addition of 10 mM trans Ca2þ
did not generate a noticeable unitary Ca2þ current at 0 mV
and was without effect on Kþ currents or reversal potential
of RyR1 Arg110Trpþ Leu486Val (Fig. 8C, Table 2). Taken
together, the single-channel data indicate that the
Asn2283His mutation increases Ca2þ responsiveness and ion
selectivity for Ca2þ compared with Kþ, without altering Kþ
conductance. In contrast, the homozygous Arg110Trpþ
Leu486Val mutations abolished Ca2þ responsiveness and
Ca2þ permeation, and reduced the Kþ conductance, demon-
strating that the homozygous expression of the Arg110Trpþ
Leu486Val mutations introduces major alterations to the
channel pore.
DISCUSSION
In this report, we present data relative to newly identified
RyR1 amino acid substitutions found in patients with core
myopathies, from three families. Our results show that
different mutations are associated with different functional
outcomes: (i) the p.Ala1577Thrþ p.Gly2060Cys and
p.Arg109Trpþ p.Met485Val mutations lead to a decrease in
the amount of RyR1 expressed in skeletal muscle. (ii) Hetero-
zygosity for p.Ser71Tyrþ p.Asn2283His results in an
‘unstable’ protein that looses activity when isolated from
HEK293 cells and conveys an MHS phenotype. The mutation
responsible for the increased RyR1 sensitivity is the
p.Asn2283His. (iii) The homozygous expression of
p.Arg109Trpþ p.Met485Val also affects Ca2þ transport and
[3H]ryanodine binding, leading to Ca2þ dysregulation. In
family 2, both affected children exclusively transcribed in
muscle the paternal allele carrying the two substitutions,
despite being heterozygous at the genomic DNA level.
Figure 5. Calcium release stimulated by KCl and 4-chloro-m-cresol in myotubes derived from myoD-transduced fibroblasts established from control individuals.
Single cell intracellular Ca2þ measurements of fura-2 loaded cells in response to 150 mM KCl (A) and 600 mM 4-chloro-m-cresol (B). Top (from left): phase
contrast; resting [Ca2þ]i before the application of 150 mM KCl; 15, 20 and 50 s after the application of the indicated agonist. Myotubes were individually stimu-
lated by addition of the agonist in Krebs–Ringer buffer containing no added Ca2þ and 100 mM La3þ, thus the increase in [Ca2þ]i represents only release of
calcium from intracellular stores. Plotted trace represents change in [Ca2þ]i (fluorescence ratio 340/380 nm) of a single cell. (C) Comparison of calcium
release after pharmacological RyR1 activation myotubes and myotubes derived from myoD-transduced fibroblasts. Curves show the KCl, 4-chloro-m-cresol
and caffeine dose-dependent changes in calcium, expressed as D in fluorescence ratio (peak ratio 340/380 nm2resting ratio 340/380 nm). Each point represents
the mean (+SE) of the D fluorescence of measurements performed on five to 20 different cells. Dose–response curves were generated using the Origin software.
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Thus, in addition to more ‘conventional’ effects of mutations,
in some patients affected by core myopathies, haploin-
sufficiency or allele silencing must be verified, as the genotype
of the genomic DNA may not always reflect the transcribed
mRNA (Zhou et al., 2006, submitted for publication).
The presence of cores or areas devoid of oxidative enzyme
activity and mitochondria exhibiting variable degrees of
myofibrillar disruption, is a non-specific feature occurring in
several neuromuscular disorders but appears to be a particular
feature associated with mutations in the RYR1 gene (33,34). In
CCD, the large centrally located cores affecting an appreciable
number of sarcomeres are predominantly caused by dominant
mutations in the RYR1 gene and cause dysregulation of myo-
plasmic Ca2þ homeostasis by affecting the amount of Ca2þ
released after RyR1 activation (7,9,10). In other cases, the
presence of multiple small cores, with several focal areas
per fibre affecting only a few sarcomeres have been associated
with recessive mutations in the RYR1 gene; for one of these
(the p.Pro3527Ser substitutions), we were able to show that
its presence at the homozygous state also affects the amount
of Ca2þ released after direct pharmacological activation of
the RyR1 (30). Though some clinical features of patients
with minicore myopathy may appear to overlap with those
observed in patients with CCD, the two conditions can be dis-
tinguished, so it is not surprising that the functional effects of
the underlying genetic defects are dissimilar. Of the three
compound heterozygous mutations we investigated in this
study, we found that the p.Ala1577Thr þ p.Gly2060Cys did
not affect Ca2þ homeostasis in any discernable way, i.e. the
resting [Ca2þ], the pharmacological activation of Ca2þ
release, the RyR1-dependent IL-6 release (data not shown)
and the single-channel properties of recombinant channels
harbouring these mutations were unaffected. Thus, either
these substitutions are unrelated to the core myopathy and
search for mutation(s) in other genes must be undertaken or
the effect of the two substitutions operates by a distinct mech-
anism, for example, the mutations may interfere with the stab-
ility of the RyR1 macromolecular complex within the skeletal
muscle. In line with this hypothesis, we found that the relative
amount of RyR1 protein present in the muscle biopsy from the
patient was significantly decreased, whereas the overall level
of RyR1 transcript in the patient’s muscle and the amount of
RyR1 protein over-expressed in HEK293 cells transfected
with the cDNA carrying these substitutions were not affected.
Thus, the concomitant presence of both substitutions leads to a
decrease in the stability of the RyR1 complex causing partial
depletion of RyR1 Ca2þ channels in the skeletal muscle tissue
of the patients. A similar finding was reported by Monnier
et al. (35) in a patient with MmD and ophthalmoplegia carry-
ing a homozygous splicing RYR1 mutation; in their patient, the
presence of a cryptic splicing mutation resulted in a 90%
decrease in the normal RYR1 transcript in skeletal muscle.
As to family 2, western blot analysis revealed that the
p.Arg109Trpþ p.Met485Val substitutions were also
accompanied by a reduction in the amount of RyR1 expressed
in muscle tissue. Intracellular Ca2þ measurements on myo-
tubes derived from MyoD-transduced fibroblasts showed
little or no functional effects of the mutations at the hetero-
zygous state. However, transcription analysis disclosed a
fundamental difference between skeletal muscle and MyoD-
transduced myoblasts, as the former tissue was monoallelic,
whereas the latter showed biallelic transcription. It is therefore
not surprising that the Ca2þ measurement in the MyoD-
transduced myotubes did not reveal alterations in Ca2þ
homeostasis. Importantly, when HEK293 cells carrying
Figure 6. Resting calcium concentration of human myotubes from control
individuals and individuals bearing the indicated RYR1 substitutions. Histo-
grams on the left: average resting myoplasmic [Ca2þ] of cells from controls,
healthy parents and affected family members bearing the indicated RYR1 sub-
stitutions. Measurements were made on myotubes derived from myoD-
transduced fibroblasts 6 days after differentiation. Histograms on the right:
average resting myoplasmic [Ca2þ] of myotubes from controls and from
patient harbouring the compound heterozygous p.Ala1577Thrþ
p.Gly2060Cys substitutions. Measurements were made on cells established
from muscle biopsies and differentiated into myotubes for 7–10 days.
Values are the mean (+SE, n ¼ 41–157) analysed cells. The [Ca2þ]i was
measured using the fluorescent Ca2þ indicator fura-2, in Krebs–Ringer con-
taining 1 mM CaCl2 and 100 mM La
3þ. The resting [Ca2þ]i was significantly
higher only in cells harbouring the compound p.Ser71TyrþAsn2283His com-
pared with controls (P, 0.00001).
Table 1. Ability of cells carrying the indicated RYR1 mutations to release
calcium after pharmacological RyR1stimulation
Patient KCl Rmax Caff Rmax
MyoD myotubes control 0.25+ 0.03 0.36+ 0.03
Myotubes from control 0.22+ 0.04 0.29+ 0.03
Family 1 A1577T heterozygous 0.27+ 0.04 0.33+ 0.04
G2060C heterozygous 0.29+ 0.07 0.21+ 0.06
A1577TþG2060C
compound heterozygous
0.32+ 0.04 0.31+ 0.09
Family 2 Control mother 0.28+ 0.04 0.25+ 0.06
R109WþM485V
heterozygous father
0.21+ 0.04 0.10+ 0.07
R109WþM485Vþ
heterozygous childrena
0.21+ 0.01 0.11+ 0.02
Family 3 S71Yþ N2283H compound
heterozygous
0.24+ 0.04 0.17+ 0.03
aMyoD-transduced fibroblasts from these patients carried the same geno-
type as the unaffected father and were heterozygous for both substi-
tutions, whereas muscle from the patients only expressed the mutated
allele.
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recombinant homozygous channels were analysed, the results
were different: channels bearing the two substitutions inher-
ited from the father were unable to transport Ca2þ and did
not bind [3H]ryanodine. Of the two substitutions that were
co-expressed, the p.Arg109Trp alone was sufficient to signifi-
cantly diminish [3H]ryanodine binding to recombinant RyR1.
Therefore, in this family, two mechanisms may partake in
causing the myopathy: Ca2þ dysregulation due to the homozy-
gous expression of the pArg109Trp residue in the patient’s
skeletal muscle and the concomitant instability of the RyR1
carrying both homozygous substitutions leading to a reduction
in the levels of RyR1 protein within skeletal muscle. In this
context, it should be mentioned that the clinical phenotypes
of patients from both families 1 and 2, in whom we found
partial depletion of endogenous RyR1 Ca2þ channels, were
more severe compared with the patient from family 3.
As far as the p.Ser71Tyrþ p.Asn2283His substitutions found
in family 3 are concerned, our results demonstrate that their pre-
sence leads to unstable channels because no [3H]ryanodine
binding was observed on microsomes from transfected
HEK293 cells even though control levels of RyR1 were detected
on western blots from transfected HEK293 cells and in muscle
biopsies. Thus, though in family 3 the mutations do not lead to
a significant reduction in RyR1 protein content, we can hypoth-
esize that they affect the stability of the RyR1 macromolecular
complex. An additional observation emerging from this study is
that myotubes carrying the p.Ser71Tyrþ p.Asn2283His substi-
tutions had a significantly higher resting [Ca2þ] and a shift in the
sensitivity to pharmacological RyR1 activation, typical features
of MHS (24,26,36), and our results support that p.Asn2283His
substitution is responsible for conveying the MHS phenotype.
This study also explored the possibility of using primary
cultures of fibroblast to study the defects of the protein
machinery involved in skeletal muscle E–C coupling, when
primary muscle cell cultures are not available. This system
offers obvious advantages including the ease of obtaining
skin patch biopsies even from children, the capacity of fibro-
blasts to proliferate rapidly in culture and to be induced to
differentiate into myotubes after transduction with MyoD.
Nevertheless, our study also has identified some limitations
associated with the use of such cells as (i) the cell’s genotype
should be carefully evaluated in order to confirm that it
matches that of the patient’s muscle, in order to exclude silen-
cing for the mutation(s) under investigation. (ii) Their resting
[Ca2þ] is slightly, but significantly lower than that found in
myotubes derived from primary muscle cultures and their
response to 4-chloro-m-cresol does not saturate. The latter
observation may be due to the fact that such cells may also
express type 3 RyR which may be activated at millimolar con-
centrations of 4-chloro-m-cresol (37,38). As to higher resting
[Ca2þ] of myotubes derived from primary muscle cell cul-
tures, this probably reflects the pathways which are undertaken
during myoblast differentiation: during ‘physiological’
myogenesis, the expression of Kir2.1 channels on the plasma
membrane cause myoblast hyperpolarization, activation of
myogenin and MEF-2 transcription factors and the appearance
of T-type Ca2þ channels which increase the myoplasmic Ca2þ
concentration by allowing an influx of Ca2þ through the
plasma membrane (39,40). In contrast, transduction with
MyoD artificially induces fibroblasts to initiate a myogenic
Figure 7. Functional properties of WT and mutant RyR1 channels. (A) Bmax
values of [3H]ryanodine binding to WT-RyR1, RyR1 single-site mutants
Ala1578Thr (AT), Ser2060Cys (GC), Arg110Trp (RW), Leu486Val (LV),
Ser71Tyr (SY) and Asn2283His (NH), RyR1 double mutant RW/LV and
single-site mutants ATþGC and SYþNH transfected in 1:1 ratio. Data
are the mean+ SE of three to 12 experiments. (B) Ca2þ dependence of
[3H]ryanodine binding to WT-RyR1 and RyR1 mutants. Specific [3H]ryano-
dine binding for cells transfected with WT-RyR1 and RyR1 mutants was
determined in 250 mM KCl, 150 mM sucrose, 20 mM imidazole, pH 7.0, and
1 mM glutathione (oxidized) media containing 3 nM [3H]ryanodine and the
indicated concentrations of free Ca2þ. Data are mean of three to seven experi-
ments. SE were less than 20%. (C). Caffeine dependence of [3H]ryanodine
binding to WT and mutant RyR1s. Specific [3H]ryanodine binding to
WT-RyR1 (closed circles) and RyR1 mutants Ala1578Thr (open circles),
Ala1578Tþ Ser2060Cys (open triangles), Ser71Tyr (open squares),
Leu486Val (closed triangles) and Asn2283His (closed squares) was deter-
mined in 0.25 M KCl, 20 mM imidazole, pH 7 solution containing 0.5 mM
free Ca2þ, 4 nM [3H]ryanodine and indicated concentrations of caffeine.
Data are the mean+ SE of three to 12 experiments.
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differentiation without the coordinated and stepwise activation
of physiological transcription factors.
In conclusion, we have identified novel RYR1 substitutions
in patients with core myopathies and demonstrate that the
functional impact of the mutations is complex and different
from those typically observed in patients with CCD carrying
dominant RYR1 mutations. These substitutions lead to a
decrease in RyR1 content within the muscle and/or a decrease
in the stability of isolated channels; in one case, the mutations
at the homozygous state were also accompanied by the
inability to transport Ca2þ. These results indicate the import-
ance of assessing not only the functional properties of
mutated RyR1 channels in core myopathy patients, but also,
when possible, the transcriptional status and endogenous
muscle RyR1 levels in patients.
MATERIALS AND METHODS
Materials
Fura-2/AM was from Calbiochem. Caffeine was from Merck
(Darmstadt, Germany), 4-chloro-m-cresol was from Fluka
Chemicals (Buchs, Swizerland). Mouse anti-MyoD mono-
clonal antibody was from BD Biosciences (Belgium), mouse
anti-desmin monoclonal antibody was from DAKO
(Denmark), mouse anti-slow muscle myosin monoclonal
antibody was from Chemicon (CA, USA), goat anti-DHPR
polyclonal antibody was from Santa Cruz (USA) and mouse
anti-RyR1 monoclonal antibody was from Abcam (Cambridge,
UK). The secondary biotinylated anti-mouse Ig antibody,
Hybond-ECL nitrocellulose and ECL plus Chemiluminescence
kit were from Amersham (Buckinghamshire, UK). Streptavi-
dine conjugated to Alexa Fluor-594 and Hoechst 33342 were
from Molecular Probes (Leiden, The Netherlands). RNA iso-
lation system was from Qiagen. The SuperScript
TM
III first
strand synthesis system for RT–PCR, pfx platinum DNA poly-
merase and NuPAGE Pre-cast gels were from Invitrogen.
Tissue culture media and reagents were from Invitrogen.
MyoD adenovirus (Ad5.f50.AdApt.Myod) was from Crucell
(The Netherlands). Human embryonic kidney (HEK) 293
cells were obtained from ATCC. FuGENE 6 and complete
protease inhibitors from Roche Applied Science (Indianapolis,
IN, USA). Phospholipids were from Avanti Polar Lipids
(Alabaster, AL, USA). All other chemicals were of analytical
grade.
Methods
Patients. As SEPN1 mutations have been identified in 50% of
classical severe cases with multiple cores, PCR and direct
Figure 8. Single-channel activities of WT, Arg110Trpþ Leu486Val and Asn2283His RyR1 ion channels. (A) Traces represent single-channel currents (openings
shown as downward deflections from the closed state, c) of WT RyR1 (left), Arg110Trpþ Leu486Val (middle) and Asn2283His (right) at 235 mV recorded in
symmetrical 250 mM KCl and indicated concentrations of free cis (cytosolic) Ca2þ. Averaged single-channel parameters at 2 mM Ca2þ cis were for WT-RyR1
and Asn2283His, respectively, Po ¼ 0.24+ 0.04 (16) and 0.55+ 0.07 (10), events/min ¼ 19248+ 2349 and 16509+ 1586, To ¼ 0.66+ 0.06 and
2.11+ 0.50 ms, Tc ¼ 4.82+ 1.99 and 1.46+ 0.21 ms. Channel parameters were calculated from recordings that contained a single-channel activity.P, 0.05 compared with WT. (B) Traces represent single-channel currents of WT, Arg110Trpþ Leu486Val and Asn2283His at 0 mV in symmetrical
250 mM KCl in the presence of 10 mM trans (SR lumenal) Ca2þ and 2 mM free Ca2þ cis. (C) Current voltage relationships of WT, Arg110Trpþ Leu486Val
and Asn2283His RyR1 channels in symmetrical 250 mM KCl (filled circles) and following addition of 10 mM trans Ca2þ (open circles).
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sequencing of SENP1 gene was performed in families 1 and 2
to exclude SEPN1 mutations (data not shown).
Family 1. The compound heterozygous substitutions p.Ala
1577Thrþ p.Gly2060Cys identified in the affected proband
were inherited from the unaffected mother, who carried a
G.A transition at position 4729 in exon 33 of the RYR1,
resulting in the p.Ala1577Thr substitution, and from the una
ffected father, who carried a G.T transition at position
6178 in exon 38 of the RYR1, resulting in the p.Gly2060Cys
substitution. The carrier mother previously had one misca
rriage. We obtained primary cultures of skeletal muscle cells
from the proband and skin fibroblasts from the clinically una
ffected parents, heterozygous for each substitution.
Family 2. The compound heterozygous substitutions p.Arg109
Trpþ p.Met485Val resulting from a C.T transition at pos-
ition 325 in exon 4 of the RYR1 and from an A.G transition
at position 1453 in exon 14 of the RYR1 were identified in the
homozygous state in the muscle cDNA of the two affected
children, but in the heterozygous state in their genomic
DNA. Their healthy father carried the compound heterozygous
substitutions at the genomic level; the entire RYR1 cDNA
from the skeletal muscle of the healthy mother was sequenced
and found to carry no substitutions, even in the promoter
region. A muscle MRI showed a pattern of selective involve-
ment similar to that observed in patients with CCD secondary
to C-terminal RYR1 mutations (13); however, the degree of
muscle wasting was more pronounced, corresponding to a
more severe clinical phenotype. Skin fibroblasts were obtained
from the affected children and healthy parents.
Family 3. The compound heterozygous substitutions p.Ser71
Tyrþ p.Asn2283His resulting from a C.A transition at pos-
ition 212 in exon 3 of the RYR1 and from an A.C transition
at position 6847 in exon 42 of the RYR1 were identified in the
affected proband. The father carried the heterozygous substi-
tution p.Ser71Tyr and the mother carried the heterozygous
substitution p.Asn2283His. The patient was the first child of
healthy unrelated parents. The family later had two healthy
monozygotic twins (Fig. AF1–3). Skin fibroblasts were
obtained from the proband but neither muscle tissue nor fibro-
blasts were available from the unaffected healthy parents.
Histological studies. Needle muscle biopsies were taken from
the vastus lateralis under local anaesthesia after informed
consent and processed for histological, histochemical and
ultrastructural studies according to standard procedures (41).
Skeletal muscle cell lines and myoD-transduced fibroblasts.
Human skeletal muscle cell cultures were established from a
portion of the needle biopsy as previously described (24).
Differentiation of myoblasts into myotubes was achieved by
changing the medium from standard growth medium to differ-
entiation medium [Dulbecco’s modified Eagle’ medium
(DMEM) plus 4.5 mg/ml glucose, 0.5% BSA, 10 ng/ml
EGF, 0.15 mg/ml creatine, 5 ng/ml insulin, 200 mM gluta-
mine, 600 ng/ml penicillin G and streptomycin and 7 mM
HEPES, pH 7.4).
For families 2 and 3, it was not possible to obtain myotubes
from the muscle biopsies but primary skin fibroblast cultures
were established from the probands and unaffected parents.
Functional studies were performed on fibroblasts transduced
with MyoD-encoding adenovirus in order to achieve myogenic
conversion. Briefly, cells were plated on cover slips in 35 mM
tissue culture dishes at a density of 1  106 cells/plate and
allowed to grow at 378C, 5% CO2 in growth medium
(DMEM supplemented with 10% fetal bovine serum). After
allowing the cells to grow for 24 h, the adherent fibroblasts
were infected by the addition of 1.6  108 virus particles
(vp)/plate in differentiation medium (DMEM supplemented
with 2% horse serum). After incubation for 3 h, cells were
allowed to differentiate into multinucleated myotubes by cul-
turing in DMEM plus 4.5 mg/ml glucose, 0.5% BSA, 10 ng/ml
EGF, 0.15 mg/ml creatine, 5 ng/ml insulin, 200 mM gluta-
mine, 600 ng/ml penicillin G and streptomycin, and 7 mM
HEPES, pH 7.4 for 4–7 days. Such cells express desmin
and other myofibrillar proteins and fuse into multinucleated
myotubes under appropriate culture conditions (42).
Mutation screening. Total RNA was extracted from frozen
skeletal muscle biopsies using the RNAeasy mini kit following
manufacturer’s instructions. Five micrograms of total RNA
were used for each reverse transcription reaction; complemen-
tary DNA (cDNA) was synthesized using the SuperScript III
first-strand synthesis system kit, in a final volume of 20 ml.
The cDNAs were subsequently used for the following
Table 2. Single-channel properties of WT and mutant RyR1s
Name WT Arg110Trpþ Leu486Val Asn2283His
In 250 mM KCl cis and trans
Kþ conductance (pS) 801+7 (17) 442+ 77 (9) 786+6 (10)
Po at 2 mM Ca
2þ cis at 235 mV 0.22+ 0.04 (19) 0.70+ 0.12 (7) 0.61+ 0.07 (11)
Po at 0.1 mM Ca
2þ cis at 235 mV 0.0005+ 0.0002 (4) 0.80 (2) 0.07+ 0.04 (4)
In 250 mM KCl cis and trans1 10 mM Ca21 trans
ICa2þ at 0 mV (pA) 22.7+ 0.1 (10) 0 (3) 22.7+ 0.1 (4)
Po at 2 mM Ca
2þ cis at 0 mV 0.03+ 0.01 (3) ND 0.35+ 0.14 (4)
Po at 0.1 mM Ca
2þ cis at 0 mV 0.0003+ 0.0001 (3) ND 0.17+ 0.14 (4)
Erev (mV) 9.5+ 0.2 (6) ND 12.6+ 0.2 (4)
PCa/PK 7.0 ND 10.6
Data are the mean+ SE of number of experiments shown in parenthesis.
P, 0.05 compared with WT RyR1.
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amplification reactions: 27 overlapping fragments ranging
from 400 to 1000 bp, covering the entire 15 kb coding
sequence of the RYR1 gene were amplified (primer sequences
available on request). The reaction consisted of 0.5–1 ml
cDNA as template, with 0.3 mM dNTPs, 1 mM MgSO4,
0.3 mM of each primer, 1 U platinum pfx DNA polymerase,
1 pfx amplification buffer, 1 PCRx enhancer (for some
GC-rich regions increased to three) in a total volume of
25 ml. PCR conditions were: denaturation at 958C for 5 min
followed by 30 cycles of 958C for 15 s, annealing at primer-
specific annealing temperatures (55–608C) for 30 s, extension
at 688C for 30–90 s and a final extension step of 688C for
10 min. Exon-specific primers (exons 3, 4, 14, 33, 38 and
42) were used when genomic DNA was amplified by PCR.
All PCR products were purified and directly sequenced in
both the forward and reverse directions using an ABI
3730XL by the MRC Genomics Core Laboratory.
Indirect immunofluorescence. Cells were fixed with an
ice-cold solution of acetone: methanol (1:1) and then labelled
with the following primary antibodies: mouse anti-MyoD
monoclonal antibody (1:200 dilution), mouse anti-desmin
monoclonal antibody (1:50 dilution), mouse anti-slow
muscle myosin monoclonal antibody (1:20 dilution), goat
anti-DHPR polyclonal antibody (1:1000 dilution) and mouse
anti-RyR1 monoclonal antibody (1:1000 dilution in PBS).
Cover slips were washed three times and then incubated
with anti-mouse or anti-goat biotinylated secondary antibody
(1:200 dilution) for 30 min. After three further washes, cells
were incubated at room temperature for 20 min with
streptavidin-conjugated Alexa-594 (1:1000 dilution). Cells
were washed three times and nuclei were stained with
Hoechst 33258 for 10 min. Cover slips were mounted in
aqueous mounting medium and viewed with a fluorescent
Leica DMR fluorescent microscope (Leica, Germany) linked
to a Prior filter wheel, equipped with 20/0.5 HC PL
FLUOTAR objective; images were digitally captured using
Metamorph software (Universal Imaging Inc.). All washes
and dilutions were in phosphate-buffered saline.
Intracellular calcium measurements. Changes in the intra-
cellular Ca2þ concentration, [Ca2þ]i, of the myotubes were
monitored with the fluorescent Ca2þ indicator fura-2 at the
single cell level by digital imaging microscopy as previously
described (26). Individual cells were stimulated with a
12-way 100 mM diameter quartz micromanifold computer
controlled microperfuser (ALA Scientific) as described.
On-line (340, 380 nm and ratio) measurements were recorded
using a fluorescent Axiovert S100 TV inverted microscope
(Carl Zeiss GmbH, Jena, Germany) equipped with a 20
water-immersion FLUAR objective (0.17 NA), filters (BP
340/380, FT 425, BP 500/530). The cells were analysed
using an Openlab imaging system and the average pixel
value for each cell was measured at excitation wavelengths
of 340 and 380 nm.
Changes in the [Ca2þ]i in response to caffeine and
4-chloro-m-cresol in HEK293 cells expressing WT and
mutant rabbit cDNA RyR1s was monitored with the fluor-
escent Ca2þ indicator Fluo-4. Briefly, HEK293 cells grown
on glass cover slips were washed three times with PBS
buffer and loaded with 5 mM Fluo 4-AM for 1 h at 378C in
Krebs–Ringer–Henseleit (KRH) buffer (125 mM NaCl,
5 mM KCl, 1.2 mM KH2PO4, 6 mM glucose, 1.2 mM MgCl2,
2 mM CaCl2 and 25 mM HEPES, pH 7.4). After loading,
cells were rinsed with KRH buffer to remove non-hydrolysed
fluophore and kept in KRH buffer for 30 min to complete
de-esterification. Individual cells in KRH buffer were
defined as region of interest, and average fluorescence increase
in response to addition of 10 mM caffeine or 400 mM
4-chloro-m-cresol was measured, using the program Image-
Master (Photon Technology International, Lawrenceville, NJ,
USA).
Construction of mutant cDNAs. Single and multiple base
changes of rabbit RyR1 cDNA were performed by Pfu-turbo
polymerase-based chain reaction using mutagenic oligonu-
cleotides and the QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA) as described previously
(43). Briefly, subfragments of RyR1 cDNA, subcloned into
cloning vectors, served as a template for PCR. The ClaI/
AauI (polylinker-1361) fragment was used for Ser71Tyr and
Arg110Trp mutations (corresponding to the human residues
Ser71Tyr and Arg109Trp, the AauI/NotI (1361–2514) for
Leu486Val (corresponding to the human residues
Met485Val), the AatII/PinAI (3470–5066) for Ala1578Thr
(corresponding to the human residues Ala1577Thr) the
PinAI/XhoI (5066–6598) for Ser2060Cys (corresponding to
the human residues Gly2060Cys) and the XhoI–BbrPI
(6598–7692) for Asn2283His. The complete mutated frag-
ments amplified by PCR were confirmed by DNA sequencing.
The fragments with mutations were cloned back into the orig-
inal positions by standard cloning techniques. Finally,
expression plasmids for full-length RyR1 with the mutations
were constructed by ligating three RyR1 fragments [ClaI/
XhoI (polylinker-6598), XhoI/EcoRI (6598–11767), EcoRI/
XbaI (11767-polylinker)] and pCMV5 (ClaI/XbaI) expression
vector. Nucleotide numbering is as described previously (44).
Expression of WT and mutant ryr1 proteins in hek293 cells.
WT RyR1 and mutant cDNAs were transiently expressed in
HEK293 cells transfected with FuGENE 6 according to man-
ufacturer’s instructions. Cells were maintained at 378C and
5% CO2 in high glucose DMEM containing 10% fetal
bovine serum and plated the day before transfection. For
each 10 cm tissue culture dish, 3.5 mg of cDNA was used.
Cells were harvested 48 h after transfection. Crude membrane
fractions and proteolipoosmes containing the purified RyR1s
were prepared in the presence of protease inhibitors as
described (43).
Immunoblot analyses. Skeletal muscle proteins were extracted
in sample buffer consisting of 75 mM Tris–HCl, 1% SDS, plus
a cocktail of protease inhibitors (antipain, aprotinin and leu-
peptin). Thirty microgram of proteins were resolved using a
NuPAGE Pre-cast gels (3–8% Tris-acetate, Invitrogen) and
then transferred electrophoretically to nitrocellulose mem-
brane. Nitrocellulose membrane was blocked in 10% semi
skimmed milk in Tris-buffered saline buffer and then probed
with mouse anti-RyR1 monoclonal antibody and mouse anti-
desmin monoclonal antibody at room temperature for 1 h.
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After washing, membranes were incubated with
HRP-anti-mouse IgG for 1 h at room temperature. Immunor-
eactivity was visualized using chemiluminescence.
Twenty micrograms protein of crude membrane fractions
prepared from HEK293 cells were separated by 3–12%
SDS/PAGE, transferred to polyvinylidene difluoride mem-
branes and probed with antibody specific for RyR1 as
described (44). Western blots were developed using
3,3-diaminobenzidine and H2O2 and quantified using Kodak
Digital Science ID.
[3H]Ryanodine binding. [3H]Ryanodine binding experiments
were performed with crude membrane fractions prepared
from HEK 293 cells. Unless otherwise indicated, membranes
were incubated with 3 nM [3H]ryanodine in 20 mM imidazole,
pH 7.0, 0.15 M sucrose, 250 mM KCl, 1 mM glutathione
(oxidized), protease inhibitors and indicated Ca2þ and caffeine
concentrations. Non-specific binding was determined using
a 1000–2000-fold excess of unlabelled ryanodine. After
20 h, samples were diluted with eight volumes of ice-cold
water and placed on Whatman GF/B filters pre-incubated
with 2% polyethyleneimine in water. Filters were washed
three times with 5 ml ice-cold 100 mM KCl, 1 mM KPipes,
pH 7.0 solution. The radioactivity remaining bound to the
filters was determined by liquid scintillation counting to
obtain bound [3H]ryanodine.
Bmax values of [
3H]ryanodine binding were determined by
incubating membranes for 4 h at 248C with a saturating con-
centration of [3H]ryanodine (30 nM) in 20 mM imidazole, pH
7.0, 0.6 M KCl, 0.15 M sucrose, 1 mM glutathione (oxidized),
protease inhibitors and 100 mM Ca2þ. Specific binding was
determined as described above.
Single-channel recordings. Single-channel measurements
were performed using planar lipid bilayers containing a
5:3:2 mixture of bovine brain phosphatidylethanolamine,
phosphatidylserine and phosphatidylcholine (25 mg of total
phospholipid/ml n-decane as previously described (45). Pro-
teoliposomes containing the purified recombinant RyR1s
were added to the cis (SR cytosolic side) chamber of a
bilayer apparatus and fused in the presence of an osmotic gra-
dient (250 mM cis KCl/20 mM trans KCl in 20 mM KHEPES,
pH 7.4, 2 mM Ca2þ). After the appearance of channel activity,
trans (SR lumenal side) KCl concentration was increased to
250 mM to prevent further fusion of proteoliposomes. To
determine Kþ and Ca2þ conductances and permeability
ratios, single-channel activities were recorded in symLeurical
250 mM KCl solution before and after addition of 10 mM Ca2þ
to the trans side and analysed as described (45).
Statistical analysis. Statistical analysis was performed using
the Student’s t-test for paired samples or using ANOVA
when more than two groups were compared. Origin computer
program (Microcal Software, Inc., Northampton, MA, USA)
was used for statistical analysis and dose–response curve
generation. The EC50 and Rmax values were calculated using
the Origin program from sigmoidal curve fitting of all the
data points.
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